-
公开(公告)号:WO2022051847A1
公开(公告)日:2022-03-17
申请号:PCT/CA2021/051239
申请日:2021-09-08
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: FEHLINGS, Michael G. , KHAZAEI, Mohammad , AHUJA, Christopher S.
Abstract: Provided herein are methods of producing spNPCs from iPSCs or NPCs, cell populations, compositions comprising cell populations, and uses of spNPCs made using the methods described. The method can comprise: a. obtaining unpatterned NPCs, the unpatterned NPCs expressing neuroectodermal markers including Pax6 and Sox1; b. priming the unpatterned NPCs of step a; and c. patterning the primed unpatterned NPCs to produce spNPCS.
-
公开(公告)号:WO2019023793A1
公开(公告)日:2019-02-07
申请号:PCT/CA2018/050926
申请日:2018-07-30
Applicant: UNIVERSITY HEALTH NETWORK
Inventor: FEHLINGS, Michael G. , KHAZAEI, Mohamad
IPC: C12N5/0797 , A61K35/30 , A61P35/00 , A61P25/28
Abstract: Provided herein are methods of producing, compositions comprising and uses of oligodendrogenic neural progenitor cells (o-NPCs), made using a combination of PDGFR agonist and thyroxin or a thyroxin analogue. The method includes; obtaining ventralized neural progenitor cells (NPCs), the ventralized NPCs expressing Sox2, Nkx6-1, decreased level of Pax6 compared to unpatterned NPCs, and elevated expression of HoxA4 compared to unpatterned NPCs; culturing the ventralized NPCs for about 12 to about 16 days (days 26-40 of Fig. 7; days 12 to 27 of Fig. 10) in neural expansion media (NEM) supplemented with i) PDGFR agonist for the about 12 to about 16 days and ii) thyroxine or a thyroxine analogue for the latter about 7 to about 9 days, to produce o-NPC expressing Sox2 and Nkx2.2, decresed level of Pax6 and Nkx6.1 compared to ventralized NPCs and elevated level of HoxA4 and Olig2 compared to ventralized NPCs.
-
公开(公告)号:EP4211229A1
公开(公告)日:2023-07-19
申请号:EP21865423.4
申请日:2021-09-08
Applicant: University Health Network
Inventor: FEHLINGS, Michael G. , KHAZAEI, Mohammad , AHUJA, Christopher S.
IPC: C12N5/0797 , A61K35/30 , A61P25/00 , A61P25/28 , C12N5/079
-
-